Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Clin Immunol. 2014 Jan 15;151(1):29–42. doi: 10.1016/j.clim.2014.01.002

Figure 3. Cytokine production in lupus-prone mice was assessed.

Figure 3

Figure 3

Figure 3

Figure 3

(A-D) TGF-β and IL-1β were measured in sera collected from mice prior to treatment (22 weeks-of-age) and following HDACi treatment every 4 weeks until mice were euthanized (38 weeks-of-age). At 22 weeks-of-age there were no significant differences in sera TGF-β or IL-1β (A,C). NZB/W mice treated with vehicle control had decreased levels of TGF-β compared to the NZW mice. The level of sera TGF-β was significantly increased in NZB/W mice treated with ITF2357 (10mg/kg) to levels comparable with NZW control mice at 38 weeks-of-age (B). There was a dose-dependent decrease in sera IL-1β in 38-week-old NZB/W mice treated with ITF2357 (n ≥ 5; *p < 0.05).